Wall Street Zen Downgrades Arcturus Therapeutics (NASDAQ:ARCT) to Sell

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday.

A number of other equities analysts have also recently commented on ARCT. Scotiabank reissued an "outperform" rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 2nd. HC Wainwright reaffirmed a "buy" rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. Canaccord Genuity Group dropped their price target on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Citigroup reaffirmed a "buy" rating on shares of Arcturus Therapeutics in a research note on Tuesday, May 13th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. One analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $54.00.

Arcturus Therapeutics Price Performance

Shares of NASDAQ:ARCT traded up $0.44 on Friday, reaching $13.80. The company's stock had a trading volume of 451,794 shares, compared to its average volume of 419,947. Arcturus Therapeutics has a 52-week low of $8.04 and a 52-week high of $25.88. The company has a market cap of $374.26 million, a P/E ratio of -5.45 and a beta of 2.27. The company has a 50-day simple moving average of $12.50 and a 200 day simple moving average of $13.95. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.64 and a current ratio of 5.64.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($1.58) by $1.06. Arcturus Therapeutics had a negative net margin of 47.47% and a negative return on equity of 27.41%. The business had revenue of $29.38 million during the quarter, compared to analysts' expectations of $25.64 million. As a group, equities research analysts anticipate that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Arcturus Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG raised its holdings in shares of Arcturus Therapeutics by 42.7% in the 4th quarter. Deutsche Bank AG now owns 24,768 shares of the biotechnology company's stock valued at $420,000 after purchasing an additional 7,417 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Arcturus Therapeutics by 6.8% in the 4th quarter. Vanguard Group Inc. now owns 1,684,561 shares of the biotechnology company's stock valued at $28,587,000 after purchasing an additional 107,635 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Arcturus Therapeutics by 3,482.9% in the 1st quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company's stock valued at $550,000 after purchasing an additional 5,085 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Arcturus Therapeutics by 52.7% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 13,461 shares of the biotechnology company's stock valued at $241,000 after purchasing an additional 4,647 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Arcturus Therapeutics by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 554,984 shares of the biotechnology company's stock valued at $9,421,000 after purchasing an additional 3,186 shares in the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.